echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Novartis' potential "first-in-class" complement inhibitor reaches phase 2 clinical endpoint

    Novartis' potential "first-in-class" complement inhibitor reaches phase 2 clinical endpoint

    • Last Update: 2021-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Today, Novartis announced that its potential "first-in-class" oral factor B inhibitor iptacopan (LNP023) has reached its primary clinical endpoint in a phase 2 clinical trial for the treatment of patients with C3 glomerulopathy (C3G).
    Significantly reduce the patient's proteinuria level

    Novartis has been actively recruiting patients for pivotal Phase 3 clinical trials

    The press release pointed out that iptacopan is expected to become the first targeted therapy for the treatment of C3G patients


    C3G is a rare and severe form of primary glomerulonephritis, which is characterized by complement disorders
    About 50% of patients progress to end-stage renal disease (ESRD) within 10 years, and 50-70% of patients have disease recurrence after kidney transplantation


    Iptacopan is an oral specific alternative complement pathway factor B inhibitor
    It may treat diseases caused by abnormal functions of multiple alternative pathways, while not affecting the immune response to microbial invasion mediated by other complement pathways, and reducing the risk of infection for patients


    ▲Factor B inhibitors can be used to treat a variety of complement-driven nephropathy (picture source: Novartis official website)

    In this phase 2 clinical trial of two patient cohorts, C3G patients who had not yet received a kidney transplant had a 45% reduction in proteinuria level compared with baseline after 12 weeks of treatment with iptacopan (p=0.

    In the cohort of patients who received kidney transplantation but C3G recurrence, iptacopan significantly reduced the deposition of complement C3 protein in the kidney (p=0.


    In addition, both patient cohorts showed persistent and strong inhibition of alternative complement pathway activity
    Based on the data from the two patient cohorts, renal function remained stable after 12 weeks


    Reference materials:

    [1] Novartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G).
    Retrieved November 4, 2021, from https:// -endpoints-in-phase-ii-study-in-rare-kidney-disease-c3-glomerulopathy-c3g-301416937.

    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.